Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Johnson and Johnson
Express Scripts
US Department of Justice
Boehringer Ingelheim

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,534,281

« Back to Dashboard

Which drugs does patent 8,534,281 protect, and when does it expire?

Patent 8,534,281 protects ARNUITY ELLIPTA, ANORO ELLIPTA, BREO ELLIPTA, and INCRUSE ELLIPTA , and is included in four NDAs.

This patent has twenty patent family members in sixteen countries.

Summary for Patent: 8,534,281

Title:Manifold for use in medicament dispenser
Abstract: A manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack comprises a body, the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from said chimney inlet to the chimney exit; the body further defining a chamber having a chamber inlet and a chamber exit, wherein the chimney exit and the chamber inlet lie side-by-side each other such that when the open blister pocket of the blister pack is positioned adjacent thereto the airflow is directed from the chimney exit to the chamber inlet via the open blister pocket to entrain the medicament powder and enable transport thereof in the airflow from the chamber inlet to the chamber exit, and wherein one or more bleed holes are provided between the chimney and the chamber such that bleed airflow is able to be directed into the chamber to disruptively impact the airflow that transports the entrained medicament powder.
Inventor(s): Davies; Michael Birsha (Ware, GB), Hailey; Mark Andrew (Ware, GB), Palmer; Mark Gregory (Ware, GB), Walker; Richard Ian (Ware, GB)
Assignee: Glaxo Group Limited (Greenforo, Middlesex, GB)
Application Number:12/096,820
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
fluticasone furoate
POWDER;INHALATION205625-001Aug 20, 2014RXYesYes► Subscribe► SubscribeY
fluticasone furoate
POWDER;INHALATION205625-002Aug 20, 2014RXYesYes► Subscribe► SubscribeY
umeclidinium bromide; vilanterol trifenatate
POWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► SubscribeY
Glaxo Grp Ltd
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► SubscribeY
Glaxo Grp Ltd
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-002Apr 30, 2015RXYesYes► Subscribe► SubscribeY
Glaxo Grp England
umeclidinium bromide
POWDER;INHALATION205382-001Apr 30, 2014RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,534,281

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0525237.4Dec 12, 2005
United Kingdom0623405.8Nov 23, 2006
PCT Information
PCT FiledDecember 11, 2006PCT Application Number:PCT/GB2006/004612
PCT Publication Date:June 21, 2007PCT Publication Number: WO2007/068896

International Patent Family for Patent: 8,534,281

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI455735► Subscribe
Taiwan200730207► Subscribe
New Zealand569035► Subscribe
Norway20082701► Subscribe
Malaysia154682► Subscribe
South Korea101387352► Subscribe
South Korea20080080636► Subscribe
Japan5518336► Subscribe
Japan2009518093► Subscribe
Israel191939► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Federal Trade Commission
Express Scripts
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus